Patents by Inventor Sergio G. Duron

Sergio G. Duron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250136564
    Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders, and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
    Type: Application
    Filed: February 1, 2023
    Publication date: May 1, 2025
    Inventors: Jason ROLAND, Sergio G. DURON
  • Publication number: 20250134882
    Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders, and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
    Type: Application
    Filed: February 1, 2023
    Publication date: May 1, 2025
    Inventors: Jason ROLAND, Sergio G. DURON
  • Publication number: 20250129032
    Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders, and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
    Type: Application
    Filed: February 1, 2023
    Publication date: April 24, 2025
    Inventors: Jason ROLAND, Sergio G. DURON
  • Publication number: 20250011324
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit transglutaminase 2 (TG2). Also described herein are methods for using such TG2 inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from TG2 inhibition.
    Type: Application
    Filed: September 6, 2024
    Publication date: January 9, 2025
    Inventors: David CAMPBELL, Justin CHAPMAN, Mui CHEUNG, Thomas R. DIRAIMONDO, Sergio G. DURON
  • Patent number: 12152026
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit transglutaminase 2 (TG2). Also described herein are methods for using such TG2 inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from TG2 inhibition.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: November 26, 2024
    Assignee: Sitari Pharma, Inc.
    Inventors: David Campbell, Justin Chapman, Mui Cheung, Thomas R. Diraimondo, Sergio G. Duron
  • Publication number: 20240358634
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or Auris interna target areas, or via perfusion into the auris media and/or Auris interna structures.
    Type: Application
    Filed: March 12, 2024
    Publication date: October 31, 2024
    Inventors: Jay LICHTER, Andrew M. TRAMMEL, Fabrice PIU, Qiang YE, Michael Christopher SCAIFE, Benedikt VOLLRATH, Sergio G. DURON, Luis A. DELLAMARY, Carl LEBEL, Jeffrey P. HARRIS
  • Patent number: 11969501
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.
    Type: Grant
    Filed: August 18, 2021
    Date of Patent: April 30, 2024
    Assignees: DOMPÉ FARMACEUTICI S.P.A., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Michael Christopher Scaife, Benedikt Vollrath, Sergio G. Duron, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris
  • Patent number: 11548892
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit transglutaminase 2 (TG2). Also described herein are methods for using such TG2 inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from TG2 inhibition.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: January 10, 2023
    Assignee: Sitari Pharma, Inc.
    Inventors: David Campbell, Justin Chapman, Thomas R. Diraimondo, Sergio G. Duron
  • Publication number: 20220040096
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.
    Type: Application
    Filed: August 18, 2021
    Publication date: February 10, 2022
    Inventors: Jay LICHTER, Andrew M. TRAMMEL, Fabrice PIU, Qiang YE, Michael Christopher SCAIFE, Benedikt VOLLRATH, Sergio G. DURON, Luis A. DELLAMARY, Carl LEBEL, Jeffrey P. HARRIS
  • Publication number: 20220040095
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.
    Type: Application
    Filed: August 18, 2021
    Publication date: February 10, 2022
    Inventors: Jay LICHTER, Andrew M. TRAMMEL, Fabrice PIU, Qiang YE, Michael Christopher SCAIFE, Benedikt VOLLRATH, Sergio G. DURON, Luis A. DELLAMARY, Carl LEBEL, Jeffrey P. HARRIS
  • Publication number: 20210220263
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with CNS modulating agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).
    Type: Application
    Filed: January 12, 2021
    Publication date: July 22, 2021
    Inventors: Jay LICHTER, Andrew M. TRAMMEL, Fabrice PIU, Qiang YE, Michael Christopher SCAIFE, Benedikt VOLLRATH, Sergio G. DURON, Luis A. DELLAMARY, Carl LEBEL, Jeffrey P. HARRIS
  • Publication number: 20210163480
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit transglutaminase 2 (TG2). Also described herein are methods for using such TG2 inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from TG2 inhibition.
    Type: Application
    Filed: August 9, 2019
    Publication date: June 3, 2021
    Inventors: David CAMPBELL, Justin CHAPMAN, Mui CHEUNG, Rhomas R. DIRAIMONDO, Sergio G. DURON
  • Patent number: 10918594
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with CNS modulating agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: February 16, 2021
    Assignees: OTONOMY, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Michael Christopher Scaife, Benedikt Vollrath, Sergio G. Duron, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris
  • Publication number: 20200230051
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.
    Type: Application
    Filed: March 19, 2020
    Publication date: July 23, 2020
    Inventors: Jay LICHTER, Andrew M. TRAMMEL, Fabrice PIU, Qiang YE, Michael Christopher SCAIFE, Benedikt VOLLRATH, Sergio G. DURON, Luis A. DELLAMARY, Carl LEBEL, Jeffrey P. HARRIS
  • Patent number: 10501493
    Abstract: Provided herein are analogs of the natural product arylomycin for the treatment of microbial infections. In some embodiments, the compounds described herein have broad spectrum bioactivity. The compounds provided herein can in other embodiments overcome the resistance conferred by single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases) and in other embodiments provide for a broader spectrum of antibiotic bioactivity compared to the natural product. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: December 10, 2019
    Assignee: RQX PHARMACEUTICALS, INC.
    Inventors: Tucker Curran Roberts, Peter Andrew Smith, David Campbell, Sergio G. Duron, Robert I. Higuchi
  • Publication number: 20190350845
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with CNS modulating agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).
    Type: Application
    Filed: June 20, 2019
    Publication date: November 21, 2019
    Inventors: Jay LICHTER, Andrew M. TRAMMEL, Fabrice PIU, Qiang YE, Michael Christopher SCAIFE, Benedikt VOLLRATH, Sergio G. DURON, Luis A. DELLAMARY, Carl LEBEL, Jeffrey P. HARRIS
  • Publication number: 20190307678
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.
    Type: Application
    Filed: April 19, 2019
    Publication date: October 10, 2019
    Inventors: Jay LICHTER, Andrew M. TRAMMEL, Fabrice PIU, Qiang YE, Michael Christopher SCAIFE, Benedikt VOLLRATH, Sergio G. DURON, Luis A. DELLAMARY, Carl LEBEL, Jeffrey P. HARRIS
  • Publication number: 20190298799
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with anti-apoptotic agent or pro-apoptotic agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).
    Type: Application
    Filed: April 17, 2019
    Publication date: October 3, 2019
    Inventors: Jay LICHTER, Andrew M. TRAMMEL, Fabrice PIU, Qiang YE, Michael Christopher SCAIFE, Benedikt VOLLRATH, Sergio G. DURON, Luis A. DELLAMARY, Carl LEBEL, Jeffrey P. HARRIS
  • Publication number: 20190192425
    Abstract: Disclosed herein are delivery devices for use in the treatment of otic disorders wherein the delivery device is administered locally to an individual afflicted with an otic disorder, through direct application or via perfusion into the targeted auris structure(s).
    Type: Application
    Filed: February 27, 2019
    Publication date: June 27, 2019
    Inventors: Jay LICHTER, Andrew M. TRAMMEL, Fabrice PIU, Qiang YE, Michael Christopher SCAIFE, Benedikt VOLLRATH, Sergio G. DURON, Luis A. DELLAMARY, Carl LEBEL, Jeffrey P. HARRIS
  • Patent number: 10272034
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: April 30, 2019
    Assignees: OTONOMY, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris, Benedikt Vollrath, Sergio G. Duron, Michael Christopher Scaife